Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07094373 · ClinicalTrials.gov registry record

Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data

A clinical trial of Chlamydial Infections, sponsored by Sanofi.

Recruiting
Registry status
533,000
Enrollment target
1
Study location

NCT07094373 is a study of Chlamydial Infections that is actively recruiting participants, run by Sanofi. The registered enrollment target is 533,000 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07094373, a study of Chlamydial Infections, is actively recruiting participants, sponsored by Sanofi.

RECRUITING
Registry status
533,000 participants
Enrollment target
1
Study location

Study Summary

This study is a pharmacoepidemiologic method study based on the secondary use of pre-existing data that examines whether TriNetX, a global health research network encompassing a worldwide electronic health record (EHR), database in the US is an appropriate real-world data (RWD) source for conducting chlamydia-related research to support the chlamydia trachomatis (CT) messenger Ribonucleic acid (mRNA) vaccine program. There are two primary objectives for this study: 1. To determine the validity of ICD, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic codes to identify patients with chlamydial infections using TriNetX EHR data in the US 2. To describe screening or diagnostic testing and treatment patterns in patients with chlamydia using TriNetX EHR data in the US There are also two secondary objectives for this study: 1. To explore the feasibility of developing a modified algorithm for identifying patients with chlamydia applicable for Merative MarketScan Commercial Claims and Encounters (CCAE) database based on the findings from the primary objectives 2. To compare patient characteristics, use of screening or diagnostic testing, and treatment patterns among patients with chlamydia between TriNetX EHR data and the MarketScan CCAE data in the US

Conditions Studied

Study Locations (1)

Massachusetts

  • University of Massachusetts Medical School - Worcester

Trial Details

FieldValue
Enrollment Target 533,000 participants
Start Date 2025-01-01
Est. Completion 2026-06-12

Sponsor

Sanofi

713 total trials

What the Registry Record Tells You About NCT07094373

The ClinicalTrials.gov registry entry for NCT07094373 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 533,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chlamydial Infections appearing as the primary indexed condition, and to 0 interventions.

NCT07094373 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07094373 about?

NCT07094373 is a clinical study titled "Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data". This study is a pharmacoepidemiologic method study based on the secondary use of pre-existing data that examines whether TriNetX, a global health research network encompassing a worldwide electronic health record (EHR), database in the US is an appropriate real-world data (RWD) source for conducting...

What is the current status of trial NCT07094373?

This trial is currently recruiting. The enrollment target is 533,000 participants. The study started on 2025-01-01. Estimated completion is 2026-06-12.

What conditions does trial NCT07094373 study?

This clinical trial studies the following conditions: Chlamydial Infections.

Who is sponsoring clinical trial NCT07094373?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07094373 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.